Puretech Health Stock Price, News & Analysis

Follica Inc. has appointed two experienced biotech executives, Tom Wiggans and Michael Davin, to its Board of Directors. Wiggans, former CEO of Dermira, will serve as Executive Chairman, bringing over 30 years of experience and leadership in biopharmaceuticals, including guiding Dermira through a successful acquisition for $1.1 billion. Davin, who has significant experience in the medical device industry, including leading Cynosure through an IPO, joins as an independent member. The company is gearing up for a Phase 3 study in male androgenetic alopecia, identifying substantial market potential.

PureTech Health (LSE: PRTC, NASDAQ: PRTC) celebrates the addition of two seasoned biotech executives to the Board of Directors of its Founded Entity, Follica. Tom Wiggans, former CEO of Dermira, becomes Executive Chairman, bringing over 30 years of biopharmaceutical experience, including successful Phase 3 trials and a $1.1 billion acquisition. Michael Davin, ex-CEO of Cynosure, joins as an independent board member, enhancing Follica's expertise in medical devices. This leadership change coincides with Follica's Phase 3 study launch for male androgenetic alopecia, potentially impacting 90 million U.S. individuals.

Vedanta Biosciences has secured a $25 million investment from Pfizer under its Breakthrough Growth Initiative. This funding will support a Phase 2 study of VE202 for treating inflammatory bowel disease (IBD), expected to start in 2021. Preliminary data from a Phase 1 study indicates that VE202 is safe and promotes durable colonization. IBD affects 1.6 million Americans, highlighting the urgent need for new treatments. Pfizer's Dr. Michael Vincent will join Vedanta's Scientific Advisory Board. Importantly, Vedanta retains control of its programs while granting Pfizer a right of first negotiation on VE202.

PureTech Health (LSE: PRTC, NASDAQ: PRTC) announces a $25 million investment in its Founded Entity, Vedanta Biosciences, from Pfizer (NYSE: PFE). This investment is part of the Pfizer Breakthrough Growth Initiative, aimed to support the Phase 2 study of VE202 in inflammatory bowel disease (IBD), expected to start in 2021. Previous Phase 1 data indicated that VE202 was safe and well-tolerated, showing promising results. Michael Vincent, Pfizer's Chief Scientific Officer, will join Vedanta's Scientific Advisory Board, while Vedanta retains control over its programs.

PureTech Health (LSE: PRTC, NASDAQ: PRTC) announced the appointment of George Farmer, Ph.D. as its new Chief Financial Officer. Dr. Farmer brings over 15 years of experience as a senior biotechnology equity analyst at BMO Capital Markets, where he provided extensive sector research. This leadership change comes as PureTech aims to capitalize on recent momentum, having initiated three clinical trials and expanded its presence in the NASDAQ Global Market.

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announced participation in the 38th Annual J.P. Morgan Healthcare Conference and other virtual events. Key presentations will include Daphne Zohar, CEO, on January 14, 2021, at 10:50am EST, and Bharatt Chowrira, J.D., Ph.D., alongside Eric Elenko, Ph.D., on January 5, 2021, at 1:00pm EST. PureTech focuses on developing innovative therapies for serious diseases, with a pipeline of 24 product candidates, two already cleared by the FDA. For more, visit puretechhealth.com.

PureTech Health (PRTC) has launched a Phase 1 clinical trial for LYT-200, targeting metastatic solid tumors resistant to current treatments. This monoclonal antibody aims to inhibit galectin-9, a protein that promotes tumor immunosuppression. The trial's primary goal is to assess safety and efficacy in escalating doses, with topline results expected in Q4 2021. Success in this trial could pave the way for a subsequent Phase 2 study exploring LYT-200’s potential in combination therapies.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced the initiation of a Phase 2a proof-of-concept study for LYT-100 in patients with breast cancer-related upper limb secondary lymphedema. This chronic condition currently lacks FDA-approved drug therapies. LYT-100 aims to address inflammation and fibrosis, with a favorable safety profile from prior studies. The study plans to enroll up to 50 patients, focusing on safety and tolerability, with results expected in Q4 2021. This initiative highlights the urgent need for effective treatments for lymphedema, potentially positioning PureTech as a leader in this overlooked area.

Follica announced encouraging results from a pilot study on treating female pattern hair loss (FPHL) using its proprietary Hair Follicle Neogenesis (HFN) device. Enrolling 11 women, the study demonstrated significant hair growth over four months, with all participants reporting improvements. The device stimulates stem cells to develop new hair follicles, complemented by a topical drug. Despite the small sample size, the outcomes highlight a notable treatment gap for women with few options available. Follica plans to advance to Phase 3 development in 2021, furthering its commitment to innovative hair loss solutions.